Navigation Links
NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate
Date:1/12/2010

d disease.  However, RSV-induced pathology in the lungs was observed in animals immunized with a formalin-inactivated RSV control.  

"We are excited to report steady progress towards the development of a vaccine against RSV, an important virus that is the leading cause of viral death in infants," said Dr. Rahul Singhvi, President and CEO of Novavax.  "A safe and effective vaccine against RSV is especially needed in very young children since RSV infection does not provoke lasting immunity.  An effective vaccine would also be important in adults, especially the elderly, where RSV illness is common.  There is currently no approved vaccine for the prevention of RSV and the market potential for such a vaccine could exceed $1 billion annually."(1)

In addition to completing this important preclinical study in cotton rats, Novavax today announced the successful scale up of the manufacturing process for the RSV-F vaccine candidate.   Material produced with this process under current Good Manufacturing Practices (cGMP) is currently being used in a formal toxicology study in rabbits.  

About Respiratory Syncytial Virus

RSV is the most commonly identified cause of lower respiratory tract illnesses in infants and young children.  Repeated infections occur throughout life causing moderate to severe cold-like symptoms.  More severe lower respiratory tract disease is also seen in elderly adults over age 65 years, similar to the severe illness witnessed in children. It is estimated that RSV infects more than 8.5 million adults annually, including the elderly over age 65 years. This virus is responsible for approximately 900,000 hospitalizations annually in the United States and major European countries. In the United States alone, RSV leads to 177,500 hosp
'/>"/>

SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... August 28, 2014 PrimeSource Building ... materials, selected SoundConnect to support their ... based audio and web conferencing platform GlobalMeet powered ... PrimeSource’s employees’ needs. SoundConnect delivers award winning ... PrimeSource Building Products will be utilizing GlobalMeet ...
(Date:8/27/2014)... Varian Medical Systems today broke ground ... Lake City manufacturing facility and allow for the consolidation ... create 1,000 new full time jobs in the state ... home to hardworking people with immense engineering and technical ... success in the manufacturing of our state-of-the-art X-ray technology,” ...
(Date:8/27/2014)... Livermore, California (PRWEB) August 27, 2014 ... (LLNL), through Lawrence Livermore National Security ... million to develop and deliver a state-of-the-art laser ... Beamlines facility (ELI Beamlines), under construction in the ... design performance, the laser system, called the " ...
(Date:8/27/2014)... mysteries is how plants survive impact by the ... rays, while using this energy for photosynthesis. The ... plant,s blades quickly dissipate the energy throughout the ... at DTU Physics have now managed to successfully ... bacteria contain light-absorbing proteins which play a role ...
Breaking Biology Technology:PrimeSource Chooses SoundConnect as Collaboration Provider 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3DTU researchers film protein quake for the first time 2
... MISSISSAUGA, ON, Dec. 14 /PRNewswire-FirstCall/ - YM BioSciences Inc. ... life sciences product development company that identifies and advances ... stages of development, today announced that it has priced ... a price to the public of $1.60 per share. ...
... CAMBRIDGE, Mass., Dec. 14, 2010 Tolerx, Inc., a ... and cancer by modulating T cell activity, today announced ... to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles ... immune system by enabling T cells to more effectively ...
... Cambridge, Mass., December 6, 2010 Utilizing a century-old ... at Harvard University have demonstrated, for the first time, ... collaboration with researchers from Hamamatsu Photonics in Hamamatsu City, ... University of Magdeburg, Germany, the advance has a wide ...
Cached Biology Technology:YM BIOSCIENCES PRICES $40 MILLION PUBLIC OFFERING 2YM BIOSCIENCES PRICES $40 MILLION PUBLIC OFFERING 3Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer 2Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer 3Capasso lab demonstrates highly unidirectional 'whispering gallery' microlasers 2
(Date:8/28/2014)... to Research Careers) Program has announced the travel award ... October 18 22, 2014 in San Diego, California. ... of students, post doctorates and scientists from underrepresented groups ... to encourage the participation of young scientists at the ... conferred 16 awards totaling $29,600., The FASEB MARC Program ...
(Date:8/28/2014)... Researchers at the University of Minnesota have developed ... to be used for muscle regeneration research as well ... FSHD. , The research is published in the current ... There is no treatment for FSHD, which is thought ... muscular dystrophy. FSHD is an unusual genetic disorder because, ...
(Date:8/28/2014)... support of peer groups and clinicians is critical ... to recent University of Georgia research. , A ... County area determined that role models for successful ... of infants. , "Mothers who received that support ... said study co-author Alex Anderson, an associate professor ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Breastfeeding study shows need for effective peer counseling programs 2
... low intake of folate and vitamin B12 increases the ... among nearly 3,000 middle-aged and elderly Finnish subjects. On ... an increased risk for the metabolic syndrome. Based on ... separate depressive subtypes with different etiologies in terms of ...
... This press release is available in Spanish . ... of amino acids and they play a fundamental role in ... in genes; they, therefore, carry out numerous functions in an ... material), bioregulating (they form part of enzymes) and a long ...
... how life began on a molecular level has been a ... on a possible mechanism by which life may have gotten ... early Earth. Researchers have proposed several competing theories for ... before the first genes or living cells came to be. ...
Cached Biology News:Lack of nutrients and metabolic syndrome linked to different subtypes of depression 2Using computational biology for the annotation of proteins 2Using computational biology for the annotation of proteins 3Model sheds light on the chemistry that sparked the origin of life 2
... Tissue Staining Kits are intended for localization ... histological and cytological specimens. These kits may ... by either R&D Systems or by other ... formation of the Avidin-Biotin Complex (ABC) with ...
... Designed specifically for high efficiency ... Low toxicity reagent proven to ... range of cell types. Results ... 95% of target gene expression. ...
... Purification Protocols covers a wide range of ... and experienced researchers in all areas of ... from the books preface illustrates just how ... research library., The chapters introduce the theoretical ...
... jetSI-ENDO is an easy-to-use siRNA transfection reagent ... endogenous genes in a variety of cell ... with an optimized, straightforward protocol. High levels ... obtained following transfection of 20 to 100 ...
Biology Products: